Safety of breastfeeding under monoclonal antibodies in the offspring of mothers with multiple sclerosis or neuromyelitis optica spectrum disorder - PubMed
3 hours ago
- #Monoclonal Antibodies
- #Breastfeeding Safety
- #Multiple Sclerosis
- Study examines safety of breastfeeding under monoclonal antibodies (mAbs) in infants of mothers with MS or NMOSD.
- 183 infants breastfed during maternal mAb therapy were compared to 183 infants of DMT-naïve mothers.
- No significant differences found in developmental delays, antibiotic use, hospitalization, or severe infections between groups.
- Physical growth and health outcomes were similar in both groups.
- Findings suggest breastfeeding under mAbs does not negatively impact infant development or health in the first 6-36 months.
- Encourages mothers with highly active neuroimmunological diseases to breastfeed while on mAb therapy.